Department of Preventive Medicine,
Department of Medicine
Mrs. Liqun Huang graduated valedictorian from one of the top universities in China. She has been working in various areas of pharmacology, molecular biology and microbiology. She has extensive experience with preclinical animal models of cancer, small animal surgery, pharmacology as well as cell culture, Western blot, ELISA and immunohistochemistry.
Over the years, Mrs. Huang has played an important role in the evaluation of novel anti-cancer and anti-inflammatory compounds as evidenced by several first-author publications in leading journals. She is confident that she can carry out these studies efficiently and with technical excellence.
Contributions to Science
1. Evaluated phospho-sulindac as a candidate drug for the treatment of DED, studying its efficacy, safety, formulation, PK, biodistribution and mechanism of action. More work is in press and in progress.
a. Honkanen RA, Huang L, Xie G, Rigas B. Phosphosulindac is efficacious in an improved concanavalin A-based rabbit model of chronic dry eye disease. Transl Res 2018;198:58-72. PMID: 29702077. Available from: https://www.sciencedirect.com/science/article/pii/S1931524418300562?via%3Dihub
b. Wen Z, Muratomi N, Huang W, Huang L, Ren J, Yang J, Persaud Y, Loloi J, Mallangada N, Kung P, Honkanen R, Rigas B. The ocular pharmacokinetics and biodistribution of phospho-sulindac (OXT-328) formulated in nanoparticles: Enhanced and targeted tissue drug delivery. International Journal of Pharmaceutics, 2019;557:273-279. Available from:
https://www.sciencedirect.com/science/article/pii/S037851731830975X?via%3Dihub
c. Honkanen RA, Huang L, Rigas B. A rabbit model of aqueous-deficient dry eye disease induced by concanavalin A injection into the lacrimal glands: Application to drug efficacy studies. J Vis Exp; 2019; in press.
d. Honkanen RA, Huang W, Huang L, Kaplowitz K, Weissbart S, Rigas B. A new rabbit model of chronic dry eye disease induced by complete surgical dacryoadenectomy. Current Eye Research; 2019; in press.
2. Evaluated the anti-cancer properties of phospho-NSAIDs.
Phospho-NSAIDs are safe and highly effective compounds on inhibiting tumor growth in various animal models. I have extensively studied their safety, efficacy and mechanism of action.
a. Huang L, Mackenzie GG, Sun Y, Ouyang N, Xie G, Vrankova K, Komninou D, Rigas B. Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds. Cancer Res. 2011 Dec 15; 71 (24):7617-27. PMCID: PMC3242900
b. Huang L, Wong CC, Cheng KW, Rigas B. Phospho-aspirin-2 (MDC-22) inhibits estrogen receptor positive breast cancer growth both in vitro and in vivo by a redox-dependent effect. PLoS One, 2014, 4;9(11):e111720. PMCID: PMC4219766
c. Huang L, Wong CC, Mackenzie GG, Sun Y, Cheng KW, Vrankova K, Alston N, Ouyang N, Rigas B. Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress. BMC Cancer. 2014 Feb 28;14:141 PMCID: PMC3941604
d. Huang L, Zhu C, Sun Y, Xie G, Mackenzie GG, Qiao G, Komninou D, Rigas B. Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: A redox/polyamine dependent effect. Carcinogenesis, 2010, 31(11): 1982-90. PMCID: PMC2966552
3. Evaluated the anti-inflammatory effects of phosphosulindac (OXT-328)
I have extensively studied the anti-inflammatory and analgesic properties of OXT-328 and other structurally similar compounds in a variety of animal and cell culture models.
a. Huang L, Mackenzie G, Ouyang N, Sun Y, Xie G, Johnson F, Komniou D, Rigas B. The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats. Br J Pharmacol., 2011, 162(7):1521-33. PMCID: PMC3057290
b. Mattheolabakis G, Mackenzie GG, Huang L, Ouyang N, Cheng KW, Rigas B. Topically applied phospho-sulindac hydrogel is efficacious and safe in the treatment of experimental arthritis in rats. Pharm Res. 2013 Jun;30(6):1471-82. PMCID: PMC4395004
4. Co-developed a novel inhibitor of NF-κB activation:
I was part of a team of four that developed a novel small molecule inhibitor of NF-κB based on our observation that annexin 1 is an endogenous inhibitor of NF-κB and that annexin 1 mediates the anti-inflammatory activity of all corticosteroids. This peptide is currently being developed for clinical applications.
a. Zhang Z, Huang L, Zhao W, Rigas B. Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo. Cancer Research, 70 (6), 2379-88, 2010. PMCID: PMC2953961
5. Screening for cooperating oncogenes in leukemia:
My early research at the National University of Singapore focused on screening for oncogenes in RUNX1+/-transgenic mice. We identified cancer genes cooperated with the RUNX1 gene in acute myeloid leukemia (AML) by retroviral integration. The selected four publications below summarize the main points of our work.
a. Huang L, Osato M, Yanagida M, Yamashita N, Ito Y. The myeloid features of BXH2 leukemias may result from lack of one copy of repetitive sequence in the long terminal repeat (LTR) viral enhancer. International Journal of Hematology, 85(2):170-172, 2007. PMID: 17321997
b. Asou N, Yanagida M, Huang L, Yamamoto M, Shigesada K, Mitsuya H, Ito Y, Osato M. Concurrent transcriptional deregulation of AML1/RUNX1 and GATA factors by the AML1-TRPS1 chimeric gene in t(8;21)(q24;q22) acute myeloid leukemia. Blood, 109(9): 4023-4027, 2007. PMID: 17244685
c. Yamashita N, Osato M, Huang L, Yanagida M, Kogan SC, Iwasaki M, Nakamura T, Shigesada K, Asou N, Ito Y. Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice. British Journal of Hematology, 131(4): 495-507, 2005. PMID: 16281942
d. Yanagida M, Osato M, Yamashita N, Liqun H, Jacob B, Wu F, Cao X, Nakamura T, Yokomizo T, Takahashi S, Yamamoto M, Shigesada K, Ito Y. Increased dosage of RUNX1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice. Oncogene, 24(28): 4477-85, 2005. PMID: 15856017
Nitric oxide-donating aspirin inhibits the growth of pancreatic cancer cells through redox-dependent signaling.
Cancer letters Jan, 2009 | Pubmed ID: 18805632
Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo.
Cancer research Mar, 2010 | Pubmed ID: 20215502
Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.
Gastroenterology Oct, 2010 | Pubmed ID: 20600034
Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect.
Carcinogenesis Nov, 2010 | Pubmed ID: 20627873
Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models.
The Journal of pharmacology and experimental therapeutics Jun, 2011 | Pubmed ID: 21422165
Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.
Cancer prevention research (Philadelphia, Pa.) Jul, 2011 | Pubmed ID: 21464038
Oxidative stress mediates through apoptosis the anticancer effect of phospho-nonsteroidal anti-inflammatory drugs: implications for the role of oxidative stress in the action of anticancer agents.
The Journal of pharmacology and experimental therapeutics Sep, 2011 | Pubmed ID: 21646387
Structure-activity relationship study of novel anticancer aspirin-based compounds.
Molecular medicine reports Sep-Oct, 2011 | Pubmed ID: 21805049
Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds.
Cancer research Dec, 2011 | Pubmed ID: 22025561
Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system.
Breast cancer research : BCR Jan, 2012 | Pubmed ID: 22293394
Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety.
British journal of pharmacology Sep, 2012 | Pubmed ID: 22489789
Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts.
Stem cells (Dayton, Ohio) Oct, 2012 | Pubmed ID: 22653497
Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles.
Pharmaceutical research Nov, 2012 | Pubmed ID: 22723123
In vitro and in vivo metabolic studies of phospho-aspirin (MDC-22).
Pharmaceutical research Dec, 2012 | Pubmed ID: 22782648
Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer.
International journal of oncology Oct, 2012 | Pubmed ID: 22842609
The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies.
Carcinogenesis Apr, 2013 | Pubmed ID: 23338686
Topically applied phospho-sulindac hydrogel is efficacious and safe in the treatment of experimental arthritis in rats.
Pharmaceutical research Jun, 2013 | Pubmed ID: 23483440
Aerosol administration of phospho-sulindac inhibits lung tumorigenesis.
Molecular cancer therapeutics Aug, 2013 | Pubmed ID: 23645590
Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice.
PloS one , 2013 | Pubmed ID: 23650499
Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics.
International journal of oncology Sep, 2013 | Pubmed ID: 23807084
Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress.
BMC cancer Feb, 2014 | Pubmed ID: 24575839
The in vitro metabolism of phospho-sulindac amide, a novel potential anticancer agent.
Biochemical pharmacology Sep, 2014 | Pubmed ID: 25044307
A novel ibuprofen derivative with anti-lung cancer properties: synthesis, formulation, pharmacokinetic and efficacy studies.
International journal of pharmaceutics Dec, 2014 | Pubmed ID: 25311177
Phospho-aspirin-2 (MDC-22) inhibits estrogen receptor positive breast cancer growth both in vitro and in vivo by a redox-dependent effect.
PloS one , 2014 | Pubmed ID: 25369051
Phospho-NSAIDs have enhanced efficacy in mice lacking plasma carboxylesterase: implications for their clinical pharmacology.
Pharmaceutical research May, 2015 | Pubmed ID: 25392229
Alkaline Ceramidase 1 Protects Mice from Premature Hair Loss by Maintaining the Homeostasis of Hair Follicle Stem Cells.
Stem cell reports 11, 2017 | Pubmed ID: 29056331
Phosphosulindac is efficacious in an improved concanavalin A-based rabbit model of chronic dry eye disease.
Translational research : the journal of laboratory and clinical medicine 08, 2018 | Pubmed ID: 29702077
The ocular pharmacokinetics and biodistribution of phospho-sulindac (OXT-328) formulated in nanoparticles: Enhanced and targeted tissue drug delivery.
International journal of pharmaceutics Feb, 2019 | Pubmed ID: 30597269
A New Rabbit Model of Chronic Dry Eye Disease Induced by Complete Surgical Dacryoadenectomy.
Current eye research Aug, 2019 | Pubmed ID: 30983427
ACERCA DE JoVE
Copyright © 2024 MyJoVE Corporation. Todos los derechos reservados